Last updated: May 25, 2026
STIVARGA (regorafenib) is manufactured through a multi-tier supply chain spanning active pharmaceutical ingredient (API), excipients, dosage-form manufacturing, and finished-dose packaging. However, supplier-level identification (named companies for each tier) cannot be produced from the information provided.
What companies supply STIVARGA API (regorafenib) and who manufactures the active ingredient?
No verified supplier list for STIVARGA regorafenib API is available in the input.
Which regorafenib API manufacturers appear in drug master files (DMFs) for STIVARGA?
No DMF-to-manufacturer mapping is available in the input.
Are there multiple regorafenib grades or polymorph supply routes used for tablets?
No formulation-grade or polymorph supply detail is available in the input.
Which excipient suppliers are used in STIVARGA tablets?
No excipient supplier data is available in the input.
What are the major tablet components and do suppliers differ by strength?
No strength-by-excipient BOM or supplier differentiation is available in the input.
How are colorants, binders, and coatings sourced for STIVARGA?
No sourcing details are available in the input.
Who are the contract manufacturers for STIVARGA finished doses (tablet manufacturing and packaging)?
No contract manufacturer names are available in the input.
Are there distinct sites for bulk tableting versus primary packaging?
No site-level manufacturing and packaging split is available in the input.
What packaging formats and suppliers are used (bottles vs cartons; desiccant packs)?
No packaging-format supplier data is available in the input.
What does the FDA labeling indicate about STIVARGA manufacturers and distributors?
No label manufacturer/distributor mapping is available in the input.
What label sections list manufacturing and distribution addresses that can be tied to suppliers?
No label text is available in the input.
How many supplier tiers exist for STIVARGA, and what are the key operational risks?
No operational risk assessment grounded in verified supplier identities is available in the input.
Where do supply constraints typically occur in regorafenib tablet supply chains?
No supply-chain constraint data is available in the input.
What common failure points affect tablet availability (API lead times, micronization, coating, packaging)?
No failure-point evidence is available in the input.
What generic or biosimilar suppliers overlap with STIVARGA manufacturing footprints?
No overlap analysis is possible without verified STIVARGA supplier identities.
Do branded and generic regorafenib manufacturers use shared API sources?
No evidence is available in the input.
What is the licensing and supply agreement landscape for STIVARGA manufacturing?
No licensing or supply agreement terms are available in the input.
Which companies control regulatory submissions that influence supplier choices (NDA holder vs manufacturer)?
No regulatory-holder mapping is available in the input.
Key Takeaways
- Supplier-level identification for STIVARGA (API, excipients, contract manufacturing, and packaging) cannot be produced from the provided information.
- No verified list of named suppliers or manufacturing sites can be mapped to STIVARGA’s regorafenib tablet supply chain.
FAQs
-
Who produces regorafenib API for STIVARGA?
Not determinable from the provided input.
-
Which companies supply the excipients used in STIVARGA tablets?
Not determinable from the provided input.
-
What contract manufacturers produce STIVARGA finished tablets and package them?
Not determinable from the provided input.
-
How can I identify STIVARGA manufacturing sites from FDA or labeling documents?
No cited document excerpts or data are provided in the input.
-
Do STIVARGA suppliers overlap with generic regorafenib suppliers?
Not determinable from the provided input.
References
No sources were provided or cited in the input.
